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The contributions of type I interferons (IFNs) to the in vitro attenuation of three temperature-sensitive (Ts) subgroup A and
one subgroup B deletion mutant RSV strains were evaluated. The ability of these vaccine viruses to induce IFNs at their
permissive and restrictive temperatures and their sensitivity to the antiviral effects of exogenous I IFNs were tested in human
lung epithelial A549 cells. Our results show that the highly attenuated and immunogenic subgroup A vaccine strain Ts1C
produced higher levels of IFN-b than its parent RSS-2 or two related strains, Ts1A and Ts1B, at their permissive temperature.
Growth of RSV-infected A549 cultures at restrictive temperatures or prior UV inactivation of the virus abolished the observed
induction of IFN-b, suggesting a strict requirement of viral replication for cellular IFN induction. The enhanced induction of
IFN-b by the highly immunogenic Ts1C at permissive temperature may be an advantageous characteristic of a live intranasal
vaccine candidate. The subgroup B strain RSV B1 and its mutant cp-52 (with SH and G gene deletions) both induced similar
but low levels of IFN-b. Hence the observed overattenuation of cp-52 in human infants is probably not due to enhanced IFN
induction during its replication in the host. The ability of cp-52, which does not express the SH and G proteins, to induce IFN-b
levels similar to those of its parent strain suggests that these viral proteins may not have a role in the induction of IFN-b in
the host. In addition, both subgroup A and B mutants and their respective parent strains were similarly resistant to the
antiviral effects of exogenous IFN-a or -b. Therefore, increased sensitivity of the mutants to IFNs does not seem to contribute
to their attenuation. © 2000 Academic PressINTRODUCTION
Respiratory syncytial virus (RSV)-induced lower respi-
ratory tract disease remains a major threat to the health
of infants and young children, resulting in an estimated
90,000 hospitalizations and 4500 deaths a year in the
United States (MMWR update 1998). RSV belongs to the
genus Pneumovirus of the family of Paramyxoviridae and
contains single-stranded negative-sense RNA as its ge-
nome (Collins et al., 1996). The genome of RSV strain A2
consists of 15,222 nucleotides (nt) and encodes two
surface glycoproteins (F, G) that are involved in viral
adsorption and fusion and are the primary components
that elicit neutralizing antibodies during RSV infection
(Johnson et al., 1987a,b). Two RSV subgroups, A and B,
can be distinguished based on sequence variations
within the F and G genes (Johnson and Collins, 1988;
Johnson et al., 1987b). A number of prototypic subgroup
A and B strains are being used in the development of
RSV vaccines (Crowe et al., 1996; Firestone et al., 1996;
Karron et al., 1997a,b; Whitehead et al., 1999).
Vaccination of infants with Formalin-inactivated RSV
(FI-RSV) during the early 1960s resulted in exacerbated
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390disease in response to natural infection due to Th2-
biased immune responses (Kim et al., 1969; Connors et
al., 1994). Live, attenuated, temperature-sensitive (Ts)
RSV mutants hold a great deal of promise as potential
vaccines due to their restricted replication in the host
and their ability to produce balanced humoral and cellu-
lar immune responses (Crowe, 1999). However, one of
the difficulties in developing live RSV vaccines has been
the identification of attenuated strains that have
achieved a satisfactory balance between attenuation
and immunogenicity because attenuation was often as-
sociated with reduced immunogenicity (Crowe et al.,
1996).
The induction of the IFN class of cytokines following
viral infection is known to play a significant role in the
host-mediated viral attenuation. The efficiency of this
so-called “innate immunity” is often dependent on the
interplay between the ability of host cells to produce IFN
in response to infection and the sensitivity of virus rep-
lication to the antiviral effects of these host-induced
IFNs.
A number of viruses have, however, developed com-
plex and elaborate mechanisms to evade this first line of
host defense (Ploegh, 1998; Smith, 1996). Analyses of
measles and Sendai (SeV) virus strains have led to the
identification of distinct viral subpopulations that differ in
their induction of and sensitivity to IFNs (Carrigan and
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Viscomi, 1998). Several reports also suggest a correla-
tion between a viral Ts phenotype and sensitivity to IFNs,
as is the case for vaccinia and influenza viruses (Atkin-
son and Lancashire, 1976; Diaz-Guerra et al., 1993;
atada et al., 1999). It is possible that the enhanced
nduction of IFNs in the host or increased sensitivity of
irus replication to IFNs contributes to the overall atten-
ation of some of the Ts or host range mutants strains of
SV. Moreover, the types and levels of immune re-
ponses produced in vivo in response to viral infection
are often dependent on balanced induction and coordi-
nated expression of a variety of cytokines including IFNs
(Whitton and Oldstone, 1996). Thus, any imbalance in the
well-orchestrated cytokine expression during infection
by live, mutant vaccine viruses can lead to over- or
underattenuation of the virus, thus affecting its immuno-
genicity, and more important, to undesirable inflamma-
tory or immunopathological consequences in the host
(Pullan and Hey, 1982; Crowe, 1999).
Little information is available regarding the IFNs in-
duced during the replication of the live, attenuated RSV
vaccine candidates that are currently being used in clin-
ical trials. Although experimental RSV infection has been
shown to induce Th1-biased protective immune re-
sponses in animal models (Graham et al., 1993; Connors
et al., 1994; Openshaw, 1995), the immune responses
elicited by a diverse human population may be difficult to
predict. Therefore, a vaccine strain that further favors
protective cellular and humoral immune responses
through the induction of appropriate cytokines would be
desirable. A potential strategy would be to identify mu-
tant virus strains that naturally induce cytokines such as
type I or II IFNs or IL-2 in the host during their replication
and to study their effects on their attenuation and pos-
sibly immunogenicity.
In this study, three RSV subgroup A Ts mutant strains,
Ts1A, Ts1B, Ts1C (with restriction temperatures of repli-
cation at 39, 38, and 37°C, respectively), and one sub-
group B deletion mutant, cp-52, were tested in human
lung epithelial A549 cells for (a) their ability to induce
type I IFNs at their permissive and restrictive tempera-
tures and (b) their sensitivity to the antiviral effects of
exogenous type I IFNs. These RSV subgroup A and B
mutants possess defined genetic lesions that contribute
to their Ts and/or attenuated phenotypes (Tolley et al.,
1996; Karron et al., 1997a; Crowe et al., 1996). Although
mutations at nt positions 731 and 736 of the viral poly-
merase are considered responsible for the Ts and atten-
uation phenotypes of these subgroup A strains (Tolley et
al., 1996), very little is known about other factors that may
have contributed to their attenuation phenotype. In addi-
tion, immunization of human adult volunteers with these
RSV strains produced less severe disease and, in the
case of Ts1C, also resulted in sero-conversion levels that
were indistinguishable from the RSS-2 parent (Tolley etal., 1996), thus making it a favorable vaccine candidate.
However, the reason(s) for its enhanced immunogenicity
compared to Ts1A or Ts1B is not known.
RSV B1 cp-52/2B5, hereafter referred to as cp-52, is a
subgroup B mutant strain derived from the RSV B1 wild-
type virus through 52 passages at low temperature
(Crowe et al., 1996). This mutant contains a substantial
genomic deletion that eliminates the synthesis of the SH
and G glycoproteins in RSV-infected cells, possibly con-
tributing to its attenuated phenotype (Karron et al.,
1997a). Clinical trials demonstrated that cp-52 was over-
attenuated in seronegative human infants despite its
ability to replicate in Vero (simian kidney origin) cells to
an extent similar to that of its wild-type parent (Karron et
al., 1997a). The reason(s) for the overattenuation of this
mutant in infant subjects is not known. Further study of
the replication of this strain in human lung cells and the
cytokine factors such as IFNs that are induced during
infection may lead to a better understanding of their role
in the infectivity and attenuation of this virus. In addition,
the role, if any, of the missing RSV G and SH glycopro-
teins in the induction IFNs leading to the attenuation of
viral replication may be evaluated. Glycoproteins of
some of the related paramyxoviruses such as Parainflu-
enza types 1 (SeV) and 4 (PIV4) or Newcastle Disease
Virus (NDV) have been shown to induce IFN in the
absence of viral replication (Ito and Hosaka, 1983; Ito et
al., 1994; Jestin and Cherbonnel, 1991), and it is not
known if RSV glycoproteins have a similar capability. If
RSV glycoproteins alone are capable of inducing IFNs in
the host, they may influence the attenuation and immune
responses of the recombinant chimeric vaccine candi-
dates (Jin et al., 1998; Whitehead et al., 1999).
In this study, we hypothesized that the attenuation of
some of these RSV mutant strains may be in part due to
variations either in their ability to induce IFNs in the host
or in their sensitivity to IFNs. We tested this hypothesis
by infection of human pulmonary epithelial A549 cell line
with attenuated or their parent RSV strains and evaluated
their ability to induce IFNs or to replicate in the presence
of exogenously added IFNs. Finally we attempted to find
a correlation, if any, between our cell culture data and the
available information from previous in vivo studies on the
attenuation and immunogenicity of these vaccine candi-
dates (Tolley et al., 1996).
RESULTS
Induction of antiviral activity in A549 cells
by RSV mutants
To determine whether the observed attenuation of
RSV subgroup A and B strains is related to an increase
in the production of type I IFNs, A549 cells were
infected with the mutants and their parent strains and
analyzed for their ability to induce IFN at permissive
temperature (32°C). Supernatants and cellular RNA
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392 LOVEYS, KULKARNI, AND ATREYAwere harvested 48 h post-infection (p.i.) and evaluated
for the presence of antiviral activity and IFN mRNA,
respectively. As shown in Fig. 1, the subgroup A RSV
mutant strains Ts1A and Ts1B induced antiviral activity
that was comparable to or lower than that of their
parental strain RSS-2, while Ts1C, the most-attenuated
mutant (restrictive temperature, 37°C), induced antivi-
ral activity that ranged from four- to ninefold greater
than that of its parent. This was consistently observed
in three independent experiments. In contrast, both
subgroup B strains induced low antiviral activity and
the level of antiviral activity induced by cp-52 mutant
as about half of that induced by its parent (Fig. 1).
hese data indicate that during in vitro infection of
549 cells, RSV and its attenuated mutant viruses are
apable of stimulating low but detectable antiviral
ctivity that is functional against vesicular stomatitis
irus (VSV)-induced CPE in MDCK cells. The most-
ttenuated RSV strain induced the most antiviral ac-
ivity at permissive temperature. Similar results were
bserved even with increasing virus loads of 1 or 3
FU/cell, tested at 32°C (data not shown). We also
valuated the samples shown in Fig. 1 for antiviral
ctivity on WISH cells and found that, although this cell
ine was less sensitive to IFN-b, the relative antiviral
ctivities were identical to those determined on MDCK
ells (data not shown). Neutralization by antisera
aised against specific IFNs further indicated that the
FIG. 1. Production of antiviral activity by A549 cells infected by RSV
subgroup A and B strains. Approximately 1 3 106 aged A549 cells were
nfected with indicated viruses at a m.o.i. of 0.5 PFU/cell, were ad-
orbed for 12 h at 32°C, and were harvested at 48 h p.i. Infectious virus
rom infected culture supernatants was UV inactivated and assayed for
ntiviral activity by plaque-reduction assay in MDCK cells with vesic-
lar stomatitis virus (VSV) as the challenge virus. Assay results repre-
ent endpoint dilutions required to reduce VSV induced CPE by 50%.
esults from three independent experiments were shown. The activi-
ies of the RSV subgroup A and B strains were normalized relative to
heir respective parent virus.ntiviral activity in the virus-infected cell supernatants
as due to IFN-b (data not shown).
s
Dnduction of IFN-b mRNA by RSV vaccine candidates
We next used IFN-specific RT–PCR to determine
whether the antiviral activity observed in A549 cell su-
pernatants infected with RSV parent and vaccine strains
was associated with an increase in intracellular type I
IFN (a or b) mRNA. The conditions for detection of IFN
RNA were optimized by incubating the A549 cell cul-
ures for 7 days before viral infection (aging) and also by
ncubating the infected cultures at 32°C. Total cellular
NA from each sample was analyzed for the induction of
FN-a, IFN-b, RSV nucleoprotein (RSV N), and ribosomal
14 (RS14) mRNA. As shown in Fig. 2A, A549 cells were
ermissive to infection by RSS-2 and its attenuated Ts
utants as the level of RSV N protein mRNA present in
ach mutant sample is similar to that in its respective
arent. IFN-a was not detected in any of the samples
ested. In contrast, while very low or no IFN-b mRNA was
detected in cells infected with RSS-2, Ts1A, or Ts1B
strains, infection with the Ts1C strain induced signifi-
cantly higher levels of IFN-b mRNA than any of its rela-
tives. Although the levels of IFN-b mRNA induced could
ot be reliably quantitated, these results were consistent
ith the relative antiviral activity induced by these vi-
uses (Fig.1). The observed differences in IFN-b mRNA
evels do not appear to be due to differences in viral
eplication or RNA sample amounts as indicated by the
imilar quantities of RSV N and the housekeeping RS14
RNA specific products. Similarly we found that cp-52
nduced levels of IFN-b mRNA similar or slightly higher
han those of its parent virus, RSV B1, under similar
eplication conditions (Fig. 2A).
FIG. 2. Induction of IFN mRNA by RSV subgroup A and B viral strains.
pproximately 1 3 106 aged A549 cells were infected with indicated
iruses at an m.o.i. of 0.5 PFU/cell, were adsorbed for 12 at at 32°C, and
ere harvested at 48 h p.i. (A) RT–PCR analysis of IFN mRNA. RT–PCR
erformed on total RNA from RSV-infected samples using oligonucle-
tide primers specific to amplify 247 and 557 bp IFN-a and IFN-b
RNA products, respectively. RT–PCR of RSV N mRNA and Ribosomal
14 (RS 14) transcripts produced expected-size products of 441 and 143
p, respectively, and indicate the level of viral replication and RNA
ample loading. (B) Southern blot analysis of RSV subgroup A strains.
T–PCR products were separated on 2.0% agarose-TBA gel, trans-
erred to NYTRAN membranes and hybridized with a 32P-labeled cDNA
robe derived from cloned human IFN-b. The samples for Southern blot
nalysis were from a similar but separate experiment. Un, uninfectedA
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aample; Ctrl, control IFN-a or -b PCR product from A549 chromosomal
NA or control RSV N PCR product from a RSV N containing plasmid.
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393INDUCTION OF IFN-b BY RSV VACCINE STRAINSThe specificity of the RT–PCR products obtained by
using IFN-b-specific primers was confirmed by Southern
blot analysis. As shown in Fig. 2B, the [32]P-dCTP-labeled
IFN-b probe selectively hybridized to the 557-bp IFN-b
PCR product generated from the RNA of RSS-2- and
Ts1C-infected samples but not from the RNA of the un-
infected control sample. Low hybridization signals were
detected in the Ts1A and Ts1B sample lanes after long
exposure (data not shown). PCR amplification of chro-
mosomal DNA isolated from untreated A549 cells served
as the positive control in these experiments.
Induction of IFN-b mRNA at permissive or restrictive
temperatures
We next evaluated whether the induction of IFN-b was
ependent on viral replication by infecting A549 cells with
nfectious or UV-inactivated viral strains at permissive
32°C), physiological (37°C), or restrictive temperatures
40°C). RSV B1 and cp-52 were evaluated at 32 and 37°C.
FIG. 3. Induction of IFN-b mRNA by RSV subgroup A strains at
permissive and restrictive temperatures. Approximately 1 3 106 aged
549 cells were infected with indicated infectious or UV-inactivated
iruses at (A) permissive (32°C), (B) physiological (37°C), and (C)
estrictive (40°C) temperatures and harvested at 48 h p.i. RT–PCR
nalysis of the total RNA was performed with specific primers for
FN-b, RSV N or ribosomal S14 RNA as described. Un, uninfected
sample; Ctrl, control IFN-b PCR product from A549 chromosomal DNA
or control RSV N PCR product from a RSV N containing plasmid.esults of these analyses are shown in Figs. 3 and 4.
At the permissive temperature of 32°C, the subgroup Atrains RSS-2, Ts1A, and Ts1B produced only low levels
f IFN-b mRNA when compared to Ts1C (Fig. 3A). These
ifferences did not appear to be due to the differences in
iral replication or unequal RNA amounts since RSV N
rotein and RS14 amplification products are similar in
hese samples. In each case, UV inactivation of viral
eplication (as evidenced by the absence of viral N
RNA) effectively ablated the observed IFN-b mRNA
nduction in these samples.
Next, the ability of these vaccine strains to replicate
nd induce IFN-b mRNA at physiological (37°C) temper-
tures was evaluated. As shown in Fig. 3B, RSS-2, Ts1A,
nd Ts1B replicated equally well at 37°C, while Ts1C did
ot, confirming its restriction at this temperature. With
egard to the IFN induction, RSS-2 induced a very low
evel of IFN-b mRNA, while none was detected in any of
the vaccine strains. UV treatment abolished even the
small induction of IFN-b mRNA seen by RSS-2, further
upporting the requirement of viral replication for IFN
nduction. Similarly, at 40°C (the restriction temperature
or all three mutants), Ts1A, Ts1B, and Ts1C were unable
o replicate at this temperature and therefore did not
nduce IFN-b mRNA. Although RSS-2 was capable of
eplication, IFN-b mRNA was not detected at this tem-
perature.
In the case of RSV subgroup B strains, infection with
B1 and cp-52 at 32°C induced similar levels of IFN-b
mRNA (Fig. 4A). Each of these viral strains replicated
FIG. 4. Induction of IFN-b mRNA by RSV subgroup B strains at 32°C
and 37°C. Approximately 1 3 106 A549 cells were infected with infec-
tious or UV-inactivated viruses at 32°C (A) or 37°C (B) and harvested at
48 h p.i. RT–PCR analysis of the total RNA was performed with specific
primers for IFN-b, RSV N or S14 ribosomal RNA as described. Un,
uninfected sample; Ctrl, control IFN-b PCR product from A549 chromo-
s
pomal DNA or control RSV N PCR product from a RSV N containing
lasmid.
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394 LOVEYS, KULKARNI, AND ATREYAequally well in A549 cells at 32°C as suggested by the
similar levels of cDNAs for RSV N mRNA. The production
of IFN-b mRNA by B1- and cp-52-infected cultures was
also dependent on viral replication since UV inactivation
abolished the observed IFN induction. Analyses per-
formed at 37°C indicate that both B1 and cp-52 induce
IFN-b mRNA at this temperature, with cp-52 inducing
lightly lower levels than B1 (Fig. 4B). The parental B1
train replicated to levels noticeably higher than cp-52 at
his temperature as indicated by the levels of RSV N
roducts although samples contained equal amounts of
NA (similar levels of RS14 products). UV inactivation
nce again ablated the viral replication and IFN-b mRNA
nduction.
etection of IFN-a or IFN-b proteins by ELISA
Since we have detected antiviral activity in the super-
natants and IFN-b mRNA in the cells of cultures infected
ith RSV subgroup A and B vaccine strains at 32°C, we
sed IFN-specific ELISA analyses to determine which
FN species were present in these samples. IFN-a was
ot detected in any of the samples tested by ELISA (data
ot shown), which correlated with the lack of IFN-a
specific PCR products observed in these samples (Fig.
2). Variable levels of IFN-b were detected in these sam-
ples as shown in Table 1.
Among the RSV subgroup A strains, only the Ts1C
mutant induced detectable levels of IFN-b protein at
32°C (Table 1). IFN-b protein was not detected in any of
the subgroup A infected samples at 37°C or 40°C, con-
sistent with the very low or lack of IFN-b mRNA seen by
T–PCR at these temperatures (Table 1 and Figs. 3B and
C).
At 32°C, infection of A549 cells by RSV subgroup B
utant cp-52 induced a low but detectable level of IFN-b
TABLE 1
Induction of IFN-b Protein by RSV Strains
IFN-b (IU/mla)
Strain 32°C 37°C 40°C
RSS-2 ,20 ,20 ,20
s1A ,20 ,20 ,20
s1B ,20 ,20 ,20
s1C 487 ,20 ,20
SVB1 20 113 ND
SVBcp52 64 ,20 ND
SVA2 ND 156 ND
IV3 ND 628 ND
Note. Values derived from a representative experiment. ND, not
etermined.
a Minimum detection limit of 20 IU/ml.protein while a lower level of IFN-b protein was induced
by the RSV B1 parent. In contrast, at 37°C, while the B1strain produced a moderate amount of IFN-b protein,
p-52 failed to induce any IFN-b protein.
To gain some perspective on the level of IFN produc-
tion by these RSV vaccine strains, we also evaluated the
levels of IFN-b protein induced by another RSV wild-type
train A2 or PIV3 at 37°C, their usual temperature of
rowth and replication. Data in Table 1 indicate that at
7°C, RSV A2 induced a significant amount of IFN-b
compared to RSS-2 wild-type virus or its derived mutants.
Only wild-type RSV B1 induced comparable or slightly
lower amounts. As expected, PIV3, a known inducer of
IFN-b (Gao et al., 1999), induced the most IFN-b, thus
validating the intrinsic ability of the A549 cell line to
produce IFN-b in response to viral infection.
Effect of type I IFNs on virus yields of subgroup A
and B RSV vaccine strains
The attenuated phenotype exhibited by the RSV sub-
group A and B vaccine strains may be, in part, due to an
increased sensitivity to the antiviral affects of the type I
IFNs. To test this possibility, A549 cells were pretreated
with varying amounts of IFN-a or IFN-b for 16 h to
stimulate host cell antiviral pathways. After IFN priming,
cell cultures were infected with each of RSV strains.
PIV3, a known IFN-sensitive virus, served as the positive
control in these experiments. Viral yields were deter-
mined as described under Materials and Methods.
Addition of increasing amounts of IFN-a significantly
nhibited viral yield of PIV3 as expected and at the high-
st dose of 10,000 IU/ml, PIV3 viral yield was reduced to
.21% ( 500-fold reduction) of the untreated control (Table
). In contrast, each of the RSV subgroup A strains was
elatively unaffected by similar doses of IFN-a with the
maximum dose inhibiting viral replication to ;10–20% of
the control sample. The Ts1C mutant appeared to be
slightly more sensitive at low dose (10 IU/ml) of IFN-a
than RSS-2, Ts1A, or Ts1B strains (P , 0.05) although at
the highest dose, its yield was decreased to the levels
similar to its relatives.
Analysis of the affect of exogenous IFN-b on the viral
yields of subgroup A strains is also presented in Table 2.
In contrast to the effects of priming with IFN-a, PIV3 was
lso less sensitive to IFN-b at similar doses, although
ncreasing doses of IFN-b resulted in a progressive in-
ibition of PIV3 replication. Subgroup A strains RSS-2,
s1A, Ts1B, and Ts1C were all only minimally sensitive to
FN-b priming with about one- to fourfold reduction in
their yields, although Ts1C seemed slightly more sensi-
tive to IFN treatment (P , 0.05) than its relatives.
Similarly, results in Table 3 indicate that both the vi-
ruses of RSV subgroup B are also resistant to the anti-
viral effects of both IFN-a and IFN-b with a decrease in
virus yield to ;8–20% (12- to 5-fold decrease) of the
untreated controls.
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In this study we investigated whether the attenuation
f either subgroup A Ts strains Ts1A, Ts1B, and Ts1C or
he subgroup B attenuated strain, cp-52, is related to
ariations in their ability induce or their sensitivity to type
T
Effect of IFN Priminga on Rep
Dose
(IU/ml) PIV3 RSS-2
IFN-a
0 100 6 0 100 6 0
10 27 6 1.5 76 6 0.5
100 7.2 6 0.2 39 6 1.1
1,000 0.89 6 0.1 25 6 1.6
5,000 0.23 6 0.03 19 6 1.5
10,000 0.21 6 0.02 15 6 2.3
IFN-b
0 100 6 0 100 6 0
10 96 6 4.5 90 6 4.6
100 54 6 13 85 6 2.7
1,000 5.1 6 1.0 79 6 7.4
5,000 1.6 6 0.2 80 6 8.3
10,000 1.4 6 0.4 66 6 2.8
a 1 3 106 A549 cells were treated with the indicated dose of human
b Viral yield was expressed as percentage of control and calculated
c Data represent averages or means 6 SD of duplicate (PIV3) or trip
TABLE 3
Effect of IFN Priminga on Replication of RSV Subgroup B Strains
Dose
(IU/ml)
Virus yieldb,c (%)
PIV3 RSV B1 cp-52
FN-a
0 100 6 0 100 6 0 100 6 0
10 0.80 6 0.2 50 6 1 59 6 22
100 0.52 6 0.2 35 6 12 38 6 16
1,000 0.64 6 0.1 28 6 3 21 6 15
5,000 0.48 6 0.03 17 6 9 23 6 19
10,000 0.58 6 0.3 18 6 7 21 6 13
FN-b
0 100 6 0 100 6 0 100 6 0
10 75 6 25 83 6 4 66 6 24
100 12 6 3.7 51 6 33 41 6 13
1,000 0.20 6 0.14 29 6 27 16 6 7
5,000 0.19 6 0.11 17 6 13 10 6 4
10,000 0.22 6 0.17 17 6 14 7.9 6 3
a 1 3 106 A549 cells were treated with the indicated dose of human
FN prior to viral infection.
b Viral yield was expressed as percentage of control and calculated
as:
Virus yield (1IFN)
Virus yield (2IFN)
3 100.
c i
v
Data represent averages or means 6 SD of duplicate (PIV3) or
riplicate experiments (RSV B1, cp-52).IFNs (a or b). Our data demonstrated that among RSV
subgroup A strains, Ts1C, the most attenuated Ts mutant
produced significantly higher levels of antiviral activity,
IFN-b mRNA, and protein compared to its related strains
SS-2, Ts1A or Ts1B, at the lowest temperature permis-
ive to the growth of all of them. Therefore, the specific
utations accumulated in Ts1C may contribute not only
o its attenuation and immunogenicity but also to its
bility to induce IFN-b at its permissive temperature.
owever, infection by Ts1A, -1B, -1C strains at their
estrictive temperatures (40 or 37°C) failed to induce
ntiviral activity, IFN-b mRNA or IFN-b protein. This
clearly demonstrates that although RSV Ts1C is inher-
ently capable of inducing IFN-b, the induction of IFN-b by
his virus is critically dependent upon its ability to repli-
ate at a given temperature. The inability of nonreplica-
ive virus to induce IFN-b was independently confirmed
n experiments where UV-inactivation abolished both vi-
us replication and IFN-b induction. Therefore, we con-
lude that although the additional mutations present in
s1C may be responsible for its increased ability to
nduce IFN-b and its attenuation at permissive temper-
ture, IFN-b may not contribute to its attenuation at
37°C since IFN-b was not induced at this temperature.
In the upper respiratory tract, i.e., nose, where the
emperatures are slightly lower (32–34°C) than the core
ody temperature (37°C), Ts1C may be able to induce
igher levels of IFN-b than its relatives. This may be
elevant in clinical trials using these RSV strains. In an
dult clinical trial where volunteers were immunized by
of RSV Subgroup A Strains
irus yieldb,c (%)
Ts1A Ts1B Ts1C
100 6 0 100 6 0 100 6 0
70 6 2.7 90 6 2.2 51 6 2.2
56 6 2.5 47 6 2.5 38 6 2.5
45 6 1.2 28 6 1.7 15 6 1.7
31 6 3.1 18 6 1.4 12 6 1.4
19 6 3.7 12 6 2.7 11 6 2.7
100 6 0 100 6 0 100 6 0
93 6 6.6 95 6 3.1 54 6 3.5
78 6 9.2 91 6 0.8 52 6 1.0
75 6 2.3 81 6 1.9 45 6 1.5
69 6 5.5 81 6 3.7 39 6 2.0
67 6 7.9 75 6 1.2 30 6 2.7
rior to viral infection.
rus yield (1IFN)
rus yield (2IFN)
3 100.
experiments (RSS-2, Ts1A, Ts1B, and Ts1C).ABLE 2
lication
V
IFN p
as:
Vintranasal inoculation (Tolley et al., 1996), 9% of the Ts1C
accinees developed upper respiratory tract illness
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396 LOVEYS, KULKARNI, AND ATREYA(URTI) and had a mean clinical severity score of 3.1. In
contrast, 42% of subjects inoculated with RSS-2 devel-
oped URTI that was noticeably more severe than those of
the Ts1C vaccinees (mean severity score of 13.7). In
addition, Ts1C was as immunogenic (68% seroconverted)
as its parent RSS-2 (70% seroconverted), while Ts1A and
Ts1B seroconverted only 35 and 50% of the volunteers,
respectively. The enhanced immunogenicity and vaccine
response rates produced by Ts1C may relate to its ability
to induce higher levels of IFN-b than Ts1A and Ts1B at
2°C. However, it is not known if the nasal washes from
he Ts1C vaccinees contain levels of IFN-b higher than
hose obtained from other vaccinees. It is possible that
he immunomodulatory effects of an increased induction
f IFN-b contribute to the increased immunogenicity of
Ts1C, making it a better vaccine candidate with a prac-
tical advantage. Even if one argues that its attenuation is
only due to the increased temperature sensitivity of its
polymerase, the enhanced immunogenicity and vaccine
response rates of Ts1C, possibly due to increased IFN-b
induction, would be desired characteristics of a favor-
able vaccine candidate.
One of the recent strategies that utilizes the ability of
immunomodulatory cytokines to enhance the immunoge-
nicity of the live vaccines is the simultaneous expression
of cloned cytokine genes by recombinant vaccine vi-
ruses. Toward achieving this goal, types I and II IFN as
well as IL-2 genes have been cloned and expressed by
recombinant DNA and RNA viruses with varying success
(Flexner et al., 1990; Leong et al., 1994; Rolf and Ram-
shaw, 1997; Giavedoni et al., 1997; Bembridge et al., 1998;
araca et al., 1998; Bukreyev et al., 1999). In one case,
he expression of the IFN-g gene by a recombinant RSV
ed to viral attenuation and favorable immunogenicity
Bukreyev et al., 1999). Our present data further support
hat selection of natural RSV Ts mutants capable of
nducing higher levels of type I IFNs may be a viable and
ational strategy for achieving desired levels of attenua-
ion coupled with enhanced immunogenicity.
We also tested an alternative possibility in which the
ttenuation of Ts1C, compared to its relatives, is due to
ts increased sensitivity to type I IFNs in A549 cells. Our
esults (Table 2) indicate that while Ts1A and Ts1B are
lmost identical to their parent RSS-2 in their resistance
o IFN-a and IFN-b, Ts1C is slightly more sensitive to
oth IFNs as evidenced by the reduction in its virus
ields. We are evaluating if this increased sensitivity is
ue to the enhanced induction of endogenous IFN-b
during infection. The observed differences between
Ts1C and its relatives were statistically significant (P ,
0.05) especially at the lower doses of IFN-a and at all
oses of IFN-b, although the overall reduction in virus
ields was 10-fold at any dose of IFN for any given virus.
his level of reduction in virus yields is not generally
onsidered very significant because the yields of many
FN-sensitive viruses are decreased by $100-fold evenat lower doses of IFNs. From our data it appears that
increased sensitivity to IFN-b per se does not have a
ajor effect in reducing viral replication and does not
eem to contribute to their attenuation. We previously
howed that another related wild-type strain, RSV A2, is
imilarly resistant to both type I IFNs and MxA, an IFN-
nducible antiviral protein (Atreya and Kulkarni, 1999).
herefore it would appear that the mutations accumu-
ated in the vaccine strains do not increase their sensi-
ivity to the antiviral effects of type I IFNs.
The overattenuation (lack of viral replication) of cp-52
bserved in seronegative children (Karron et al., 1997a)
ay be due to the induction of IFNs in human respiratory
ract in response to infection by cp-52. We tested this
ossibility in human lung epithelial A549 cells that are
apable of producing IFNs in response to viral infection.
t 32°C, cp-52 produced antiviral activity and IFN-b
mRNA levels that are very similar to or within twofold
difference of those of its parent virus. The overall levels
of antiviral activity induced by both subgroup B viruses
were very low, and hence the observed differences in the
antiviral activity induced by these two viruses may not be
significant. From our in vitro studies using A549 cells,
there does not seem to be a significant induction of
IFN-b in response to cp-52 infection that would account
for its overattenuation when compared to its parent virus.
We also tested the relative sensitivity of cp-52 and RSV
1 to both IFN-a and -b and found that both viruses were
similarly resistant to these IFNs (Table 3), and hence
increased sensitivity of cp-52 to type I IFNs does not
seem to contribute to its overattenuation.
It is also interesting to note that both the RSV B1 and
cp-52 strains induce similar but low levels of IFN-b
despite the absence of the SH and G proteins in the
mutant virus. This indicates that these RSV glycoproteins
may not have any obvious role in either suppressing or
inducing IFN-b in the host, upon viral infection. This
inding is in contrast to the related paramyxoviruses (e.g.,
eV, PIV4, and NDV) whose surface glycoproteins alone
ere shown to induce IFNs in the absence of any viral
eplication (Ito and Hosaka, 1983; Ito et al., 1994; Jestin
nd Cherbonnel, 1991). In addition, the upregulation of
HC Class I gene expression by UV-inactivated PIV3
as also suggested to be due to the induction of IFN-b
by viral glycoprotein (Gao et al., 1999). However, recent
studies with other negative-strand RNA viruses such as
VSV indicate that mutations in viral polymerase may also
be responsible for regulation of IFN induction in permis-
sive cell cultures (Awaya et al., 1999).
In addition, our results (Table 1) demonstrate for the
first time an apparent difference between RSS-2 and RSV
A2 wild-type strains in their abilities to induce IFN-b at
37°C in A549 cells. Despite their high degree of homol-
ogy (96.6%), RSS-2 differs from RSV A2 in having at least
34 deletions and two insertions in its genome (Tolley et
al., 1996). One of the major deletions occurs in the 39
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397INDUCTION OF IFN-b BY RSV VACCINE STRAINSnoncoding region of its P gene. It remains to be deter-
mined with recombinant A2 virus if this deletion, in fact,
affects IFN-b induction.
One apparent contradiction that was noticed in our
tudies is that at 37 or 40°C, although RSS-2 was able to
eplicate, no IFN-b mRNA, protein, or antiviral activity
was detected. The difficulty in detecting IFN-b mRNA at
higher temperatures (37 and 40°C) may be due to the
extremely low level of IFN-b induction by this strain or it
ay relate to a decreased IFN-b mRNA stability (Cava-
ieri et al., 1977). In fact, enhanced production of IFN has
een reported in NDV-infected Namalwa and rabbit cells
n response to lowering the culture from 37 to 32 or 25°C.
his was suggested to be due to prolonged translation of
olysome-stabilized IFN mRNA (Kognovitskaya et al.,
987; Kojima and Yoshida, 1974; Maehara et al., 1980).
The data presented here are, to the best of our knowl-
dge, the first report demonstrating the induction of
FN-b mRNA, protein, and antiviral activity in the human
pithelial A549 cell line in response to infection with
hese RSV vaccine candidates. Our data also indicate
hat the in vitro induction of IFN-b by Ts1C is coincident
with enhanced immunogenicity observed in vivo. The
data also indicate that the RSV G and SH proteins have
no obvious role in the induction of or sensitivity to these
type I IFNs during viral infection. Studies with several
different RSV subgroup A and B virus mutant strains are
currently in progress to further determine the role of type
I and type II IFNs in their attenuation and immune re-
sponses.
MATERIALS AND METHODS
Cell culture, viruses, and reagents
Human IFN-a was purchased from Sigma Chemical
Co. (St. Louis, MO) and ELISA reagent kit for detection of
IFN-a was obtained from Endogen (Woburn, MA). Human
FN-b and the ELISA kit for detection of IFN-b were both
urchased from Bio-Source International (Camarillo, CA).
olyinosinic-polycytidylic acid (poly IC) and DEAE-Dex-
ran were obtained from Pharmacia (Piscataway, NJ).
uman pulmonary epithelial carcinoma (A549), African
reen monkey kidney (BS-C-1) and human laryngeal ep-
thelial carcinoma (HEp-2) cell lines and human Parain-
luenza type 3 strain C243 were all obtained from Amer-
can Type Culture Collection (ATCC, Manassas, VA). RSV
2 strain has been described (Atreya and Kulkarni, 1999).
SV B1 and cp-52 strains (Karron et al., 1997a) were a gift
rom Dr. Brian Murphy (NAID, NIH). The RSV strains
SS-2, Ts1A, Ts1B, and Ts1C were kindly provided by Dr.
raig R. Pringle (University of Warwick, Coventry, UK) and
ave been previously described (Tolley et al., 1996). Hu-
an IFN-b cDNA (Raj and Pitha, 1981) was kindly pro-vided by Dr. Paula Pitha-Rowe (Johns Hopkins Oncology
Center, Baltimore, MD).Preparation of cell and viral stocks
A549, BS-C-1, and HEp-2 cell lines were maintained in
Earle’s minimal essential medium (EMEM) containing
10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine
L-Gln), 1% GASP, and 2.5 mg/ml Amphotericin B (Quality
iological, Gaithersburg, MD). RSS-2 and derived mu-
ants were propagated in BS-C-1 cells. Briefly, BS-C-1
onolayers were adsorbed with viruses at 37 (RSS-2) or
2°C (Ts1A, Ts1B, Ts1C) at a multiplicity of infection
m.o.i.) of 0.1 PFU/cell for 4 h. RSV B1 and cp-52 strains
ere propagated in Vero cells at 37 and 32°C, respec-
ively. Subsequently, viral inoculum was removed and
eplaced with EMEM containing 2% FBS and antibiotics.
nfection was allowed to proceed for an additional 48–96
or until the observed cytopathic effects (CPE) were
pproximately 80%. Cell monolayers and supernatants
ere collected and centrifuged at 1400 rpm for 10 min.
upernatants were removed and supplemented with
/20 volume of 2 M MgSO4 and 2 M HEPES buffer (pH
.4). RSV A2 and PIV3 were propagated in HEp-2 cells at
7°C after infection at an m.o.i. of 0.1 PFU/cell for 48–72
as described previously (Atreya and Kulkarni, 1999).
iral titers were determined on HEp-2, Vero, or BS-C-1
onolayers by plaque assay (Kirsch and Johnson, 1963).
iral infections of A549 cells
A549 cells were plated onto six-well tissue culture
lates, were grown to confluence, and were aged, i.e.,
ncubated for 7 days before infection (Friedman, 1979).
pproximately 1 3 106 cells were infected with viruses at
an m.o.i. of 0.1 or 0.5 PFU/cell (or as specified) and
allowed to adsorb for 2 or 12 h, respectively. Cell mono-
layers were washed and were further incubated in 1 ml
of EMEM containing 2% FBS for 48 h or as specified.
Interferon bioassay
Supernatants from RSV-infected cell cultures were
harvested and stored at 270°C until further analysis.
Virus in the supernatant was inactivated by UV treatment
and the antiviral activity due to IFNs was determined in a
plaque-reduction assay performed in MDCK and/or
WISH cells with VSV as the challenge virus (Gresser et
l., 1974). Assays results represent the endpoint dilutions
equired to produce 50% reduction in VSV-induced CPE
Gresser et al.,1974). The antiviral activities induced by
he RSV subgroup A and B mutant strains were normal-
zed relative to those induced by their respective parent
iruses.
LISA
The concentrations of IFN-a and IFN-b protein in vi-
rus-infected cell supernatants were determined by quan-
titative enzyme-linked immunosorbent assay (ELISA).
Twofold dilutions of experimental samples were pre-
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398 LOVEYS, KULKARNI, AND ATREYApared in duplicate and assayed against serial dilutions of
respective standards as suggested by the manufacturer.
Sample concentrations were determined from the stan-
dard curves. Minimal levels of detection for IFN-a and
IFN-b were 25.6 pg/ml and 20 IU/ml, respectively.
T–PCR
Total RNA was extracted from control or RSV-infected
549 cells using TRIzol reagent (Life Technologies,
aithersburg, MD) according to the manufacturer’s pro-
ocol. Five micrograms of total RNA was incubated with
Units (U) of DNase I (Life Technologies) for 15 min at
7°C, followed by inactivation of the enzyme by adding
.5 mM EDTA at 70°C for 15 min. Equal amounts (2.5 mg)
of each sample were reverse transcribed in the presence
or absence of Moloney murine leukemia virus reverse
transcriptase (M-MLV RT) (Life Technologies) at 37°C for
1 h in a final volume of 20 ml RT mixture containing 2.5
mg/ml oligo(dT)12–18, 3 mM MgCl2, 50 mM Tris–HCl, 75
mM KCl, 250 mM each dNTPs, 10 mM dithiothreitol (DTT).
nzyme activity of M-MLV RT was inactivated by heating
t 70°C for 15 min, and then one-tenth-volume (2 ml)
aliquots were subjected to amplification by polymerase
chain reaction (PCR). PCR amplifications were carried
out in 25 ml reaction volume containing 10 mM Tris–HCl
pH 9.0 at 25°C), 50 mM KCl, 2.5 mM MgCl2, 0.1% Triton
X-100, 25 mM MgCl2, 250 mM each of dNTPs, 1.5 U Taq
DNA polymerase (Promega, WI), and 15 pmol of each
primer. PCR reactions were heat denatured at 94°C for 3
min immediately before amplification. Amplifications
were carried out for 30 cycles using a denaturation
temperature of 94°C for 30 s, annealing temperatures of
51°C (RSV N) or 54°C (IFN-b, RS14) for 30 s, and a primer
xtension temperature of 70°C for 30 s. Forward and
everse primers for the gene targets, namely, IFN-a,
IFN-b, RSV N, and Ribosomal S14 (RS14), were designed
rom published sequences as shown in Table 4 and were
T
Oligonucleotide Primers
Oligonucleotide Orientation
IFN-a 59-39 TCC
39-59 ATT
IFN-b 59-39 GCT
39-59 GAG
RSV N protein 59-39 TAA
39-59 ACG
RS14 59-39 GGC
39-59 CAG
a IFN-b forward and RSV N protein primer design was based on repo
ll others were as previously reported (Noah and Becker, 1993; Ronniynthesized by the Peptide and Nucleic Acid Laboratory,
DA.
J
touthern blot analysis
PCR reactions to detect IFN-b cDNA were performed
as described in the previous section. PCR products were
separated in 2.0% agarose–TBA gel and transferred to
0.2-mm NYTRAN (Schleicher and Schuell, Keene, NH)
embranes using TURBOBLOTTER (Schleicher and
chuell, Keene, NH), a rapid downward transfer system,
er manufacturer’s protocols. Southern blot hybridization
as performed at 65°C essentially as described (Sam-
rook et al., 1989) except for the hybridization buffer (500
M NaPO4, 10% dextran sulfate, 1% SDS, 10 mM EDTA,
1 M NaCl with 100 mg/ml freshly denatured, sheared
almon-sperm DNA). The 32P-labeled probe generated by
random-primer labeling (Life Technologies), contained
human IFN-b coding sequence (Raj and Pitha, 1981). Blot
was placed under cellophane and exposed to BioMax
X-ray film (Kodak, Rochester, NY) at 270°C in the pres-
ence of intensifying screens for 1, 4, or 24 h.
Determination of virus yields
Priming of A549 cells with IFN-a or -b before viral
infections was carried out essentially as described
(Atreya and Kulkarni, 1999). Briefly, confluent A549 mono-
layers in six-well plates were primed with 10, 100, 500,
1000, 5000, or 10,000 IU/ml doses of IFN-a or IFN-b for
6 h followed by virus infection at an m.o.i. of 0.1 PFU/
ell. Previous studies indicated that both IFN-a and -b at
the amounts used were not cytotoxic to A549 cells
(Atreya and Kulkarni, 1999). Unprimed virus-infected cul-
tures were included as an internal control for each plate
of cells infected with a given virus. PIV3, a known inter-
feron-sensitive virus (Zhao et al., 1996), was included in
ach set of experiments. Cells were adsorbed with virus
or 4 h, were washed, and then were incubated for 48 h
n EMEM containing 2% FBS and antibiotics. Infectious
irus yields using 48-h cell culture supernatants were
etermined by plaque assay in HEp-2 cells (Kirsch and
For RT–PCR Analysisa
Sequence (59-39) Product (bp)
ATGATCCAGCAG 274
CTCTGACAACCTCCC
GTTGTGCTTCTCCAC 557
AGGATCCGAGATCTTCAGTTTCG
AGCTCTACATCAT 441
GACCACAGCTTCTATGAAGTG
CGAGATGAATCCTCA 143
AGGGGTCTTGGTCC
RNA sequences for human IFN-b and RSV A2 N proteins, respectively.
1997).ABLE 4
Used
ATGAG
TCTCG
CTCCT
GCAC
CTCAA
CGTC
AGAC
GTCCohnson, 1963). The infectious virus yields of the IFN-
reated samples were determined as follows (Atreya and
a
C
G
H
I
I
J
J
J
J
399INDUCTION OF IFN-b BY RSV VACCINE STRAINSKulkarni, 1999): (number of plaques per ml of culture
supernatant obtained from IFN-treated samples) divided
by (number of plaques per ml of culture supernatant
obtained from untreated samples) 3 100. Statistical sig-
nificance of the affect of IFN priming on viral yields was
evaluated by two-way analysis of variance (ANOVA) of
ranked data using SIGMASTAT software.
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